Emergent BioSolutions Provides Update on Status of BioThrax Procurement Contract and Discussions With CDC
30 September 2016 - 11:29PM
Emergent BioSolutions Inc. (NYSE:EBS) today provided an update on
the status of its 2011 BioThrax® (Anthrax Vaccine Adsorbed)
procurement contract and the status of its discussions with the
Centers for Disease Control and Prevention (CDC) for a follow-on
procurement contract for BioThrax.
2011 Procurement ContractCDC has exercised an option to procure
all remaining BioThrax doses, thereby committing to take delivery
of the full 44.75 million doses, under the procurement contract
announced on October 3, 2011 and due to expire September 30,
2016. In concert with this option exercise, CDC has granted a
no-cost extension to enable delivery of the remaining doses to be
completed by November 30, 2016.
Follow-On Procurement ContractThe company remains in active
negotiations with CDC with respect to the Sole Source Notification
(2016-N-17905) issued in June indicating CDC’s intention to award
Emergent a contract for the purchase of 29.4 million doses of
BioThrax over five years. The company will provide more clarity
upon finalization of the contract.
BioThrax, the only anthrax vaccine licensed by the U.S. Food and
Drug Administration (FDA), is indicated for both pre-exposure
prophylaxis and post-exposure prophylaxis of anthrax disease.
About Emergent BioSolutionsEmergent
BioSolutions is a global specialty biopharmaceutical company
dedicated to one simple mission—to protect and enhance
life. We develop, manufacture, and deliver a portfolio of
medical countermeasures for biological and chemical threats as well
as emerging infectious diseases. Through our work, we envision
protecting and enhancing 50 million lives with our products by
2025. Additional information about the company may be found at
www.emergentbiosolutions.com. Follow us @emergentbiosolu.
Safe Harbor StatementThis press release
includes forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Any statements,
other than statements of historical fact, including statements
regarding the total potential realizable value of the contract, our
strategy, future operations, prospects, plans and objectives with
respect to BioThrax and any other statements containing the words
“believes,” “expects,” “anticipates,” “intends,” “plans,”
“estimates” and similar expressions, are forward-looking
statements. These forward-looking statements are based on our
current intentions, beliefs and expectations regarding future
events. We cannot guarantee that any forward-looking statement will
be accurate. Investors should realize that if underlying
assumptions prove inaccurate or unknown risks or uncertainties
materialize, actual results could differ materially from our
expectations. Investors are, therefore, cautioned not to place
undue reliance on any forward-looking statement. Any
forward-looking statement speaks only as of the date of this press
release, and, except as required by law, we do not undertake to
update any forward-looking statement to reflect new information,
events or circumstances.
There are a number of important factors that could cause the
company’s actual results to differ materially from those indicated
by such forward-looking statements, including appropriations for
BioThrax procurement under the contract; CDC’s decisions to
exercise options under the contract; and our manufacturing
capabilities and strategies. The foregoing sets forth many, but not
all, of the factors that could cause actual results to differ from
our expectations in any forward-looking statement. Investors should
consider this cautionary statement, as well as the risk factors
identified in our periodic reports filed with the SEC, when
evaluating our forward-looking statements.
Investor Contact:
Robert G. Burrows
Vice President, Investor Relations
240-631-3280
BurrowsR@ebsi.com
Media Contact:
Tracey Schmitt Lintott
Senior Vice President, Global Public Affairs
240-631-3281
SchmittT@ebsi.com
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Apr 2024 to May 2024
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From May 2023 to May 2024